Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amneal PharmaceuticalsAMRX -2.17%59 PB Ratio is 175.53 as of Aug. 06, 2026, which is 8380% above its 10-year median of 2.07. GuruFocus rates AMRX with a GF Score™ of 59/100 and a GF Value™ of $8.15 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 921 Drug Manufacturers companies, Amneal Pharmaceuticals ranks worse than 99.78% on this metric.
Amneal Pharmaceuticals Inc stock PB Ratio (=179.32) is close to 10-year high of 179.32.
The historical rank and industry rank for Amneal Pharmaceuticals's PB Ratio or its related term are showing as below:
AMRX'
s PB Ratio Range Over the Past 10 Years
Min: 0.67 Med: 2.07 Max: 187
Current: 180.7
During the past 10 years, Amneal Pharmaceuticals's highest PB Ratio was 187.00. The lowest was 0.67. And the median was 2.07.
AMRX's PB Ratio is ranked worse than 99.78% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.92
vs AMRX: 180.70
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Amneal Pharmaceuticals was 7.70% per year. The lowest was -68.40% per year. And the median was -15.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amneal Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Amneal Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Amneal Pharmaceuticals (AMRX) has a PB Ratio of 175.53 as of Aug. 06, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Amneal Pharmaceuticals and its competitors. This is 8380% above median its historical median of 2.07. Over the past decade, Amneal Pharmaceuticals' PB Ratio has ranged from 0.67 to 187.00. According to the industry distribution chart, Amneal Pharmaceuticals ranks #919 out of 921 companies in the Drug Manufacturers industry, placing it in the top 99.8%.
Is Amneal Pharmaceuticals' PB Ratio too high?
Amneal Pharmaceuticals' current PB Ratio of 175.53 is 8380% above median its 10-year median of 2.07. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 187.00. The Drug Manufacturers industry median PB Ratio is 1.92. Amneal Pharmaceuticals' value of 175.53 is 9042.2% above this industry median. Based on the distribution chart, Amneal Pharmaceuticals ranks #919 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Amneal Pharmaceuticals has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' PB Ratio compare to HIMS and KNSA?
According to the Drug Manufacturers industry distribution chart, Amneal Pharmaceuticals ranks #919 out of 921 companies for PB Ratio. This places Amneal Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 1.92. Amneal Pharmaceuticals' value of 175.53 is 9042.2% above this benchmark. Historically, Amneal Pharmaceuticals' own PB Ratio has ranged from 0.67 to 187.00 over the past decade. While the company's 10-year median is 2.07 vs. the industry median of 1.92, Amneal Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.92, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amneal Pharmaceuticals's current PB Ratio of 175.53 is 9042.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Amneal Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amneal Pharmaceuticals's current PB Ratio is 175.53, which is 8380% above median its own 10-year median of 2.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $8.15, compared to a current price of $18.08 — trading 121.8% above its estimated fair value. The current PB Ratio is 175.53, which is 8380% above median its 10-year median of 2.07 and 9042.2% above the Drug Manufacturers industry median of 1.92. Amneal Pharmaceuticals' overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current PB Ratio is 175.53 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?
Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued.
The current stock price of $18.08 is trading 121.8% above its estimated GF Value™ of $8.15.
GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for AMRX:
PB Ratio: 175.53 (8380% above median its 10-year median of 2.07)
GF Value™: $8.15 vs. price of $18.08 (121.8% above fair value)
Industry Position: 9042.2% above the Drug Manufacturers median (#919 of 921)
No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
59GF Score
Get the complete analysis for AMRX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMRX has been successfully added to your 
